Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
Shareholder Rights Advocates at Levi & Korsinsky Investigate Harmony Biosciences Holdings, Inc. (HRMY) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
UBS initiated coverage on Harmony Biosciences Holdings Inc HRMY, a commercial-stage biopharmaceutical company focused on rare neurological disorders.
HRMY or REGN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?
Is Harmony Biosciences (HRMY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Harmony Biosciences: Unnoticed Melodies Of Portfolio Growth And Pipeline Potential
Harmony Biosciences' main product, WAKIX, drives significant revenue growth, with expansion potential in treating narcolepsy and other conditions, despite past controversies. The company's strategic acquisitions, including Zynerba and Epygenix, aim to diversify its portfolio, reducing reliance on WAKIX and boosting long-term growth prospects. Harmony's financial health is strong, with substantial cash reserves and high margins, allowing continued investment in research and development.
Surging Earnings Estimates Signal Upside for Harmony Biosciences (HRMY) Stock
Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Harmony Biosciences: Advancing An Expanded Pipeline
Today, we are revisiting the biopharma name Harmony Biosciences for the first time in nearly a year and a half. The company is nicely profitable thanks to its flagship product WAKIX and Harmony has a solid balance sheet as well. Harmony Biosciences has made some recent acquisitions that greatly expanded its pipeline and peak sales potential.
Can Harmony Biosciences (HRMY) Climb 25.05% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HRMY vs. REGN: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.56 per share a year ago.
